CC趋化因子细胞受体5基因多态性与慢性丙肝干扰素疗效关联性的研究

凡豪志; 岳明; 邵建国; 薛红; 田亭; 巫晶晶; 姚敏; 黄鹏; 喻荣彬; 张云

doi:10.16462/j.cnki.zhjbkz.2018.10.010

CC趋化因子细胞受体5基因多态性与慢性丙肝干扰素疗效关联性的研究

doi: 10.16462/j.cnki.zhjbkz.2018.10.010

凡豪志^1,2,
岳明³,
邵建国⁴,
薛红⁵,
田亭⁶,
巫晶晶^1,2,
姚敏⁷,
黄鹏^1,2, ,,
喻荣彬^1,2,
张云^1,2, ,

1. 南京医科大学公共卫生学院流行病与卫生统计学系, 江苏南京 211166;
2. 南京医科大学公共卫生学院传染病重点实验室, 江苏南京 211166;
3. 南京医科大学第一附属医院感染病科, 江苏南京 210029;
4. 南通大学附属南通大学附属南通市第三人民医院消化科, 江苏南通 226001;
5. 南通大学附属南通大学附属南通市第三人民医院四病区, 江苏南通 226001;
6. 江苏省疾病预防控制中心急性传染病防制所, 江苏南京 210009;
7. 南通大学医学院免疫学系, 江苏南通 226001

基金项目:

国家自然科学基金（81703273，81502853，81773499），江苏省自然科学基金（BK20151026，BK20171054），江苏省卫计委"科教强卫工程"青年医学人才项目（QNRC2016616）

详细信息

作者简介:
凡豪志(1993-),男,安徽亳州人,在读硕士研究生。主要研究方向:传染病流行病学。

中图分类号: R394.112;R969.4
计量
- 文章访问数: 415
- HTML全文浏览量: 102
- PDF下载量: 25
- 被引次数: 0
出版历程
- 收稿日期: 2018-04-30
- 修回日期: 2018-07-28

Association of C-C chemokine receptor type 5 Gene Polymorphisms with the Effectiveness of Interferon Therapy among Patients with Chronic Hepatitis C

FAN Hao-zhi^1,2,
YUE Ming³,
SHAO Jian-guo⁴,
XUE Hong⁵,
TIAN Ting⁶,
WU Jing-jing^1,2,
YAO Min⁷,
HUANG Peng^{1,2
, ,},
YU Rong-bin^1,2,
ZHANG Yun^{1,2
, ,}

1. Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 211166, China;
2. Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing 211166, China;
3. Department of Infectious Diseases, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China;
4. Department of Gastroenterology, the Nantong Third Affiliated Hospital of Nantong University, Nantong 226001, China;
5. Fourth Ward, the Nantong Third Affiliated Hospital of Nantong University, Nantong 226001, China;
6. Department of Acute Infectious Disease Control and Prevention, Jiangsu Province Center for Disease Control and Prevention, Nanjing 210009, China;
7. Department of Immunology, Medical School of Nantong University, Nantong 226001, China

摘要

摘要: 目的探索CC趋化因子细胞受体5（C-C chemokine receptor type 5，CCR5）基因多态性与慢性丙型肝炎（chronic hepatitis C，CHC）患者治疗效果的关联，为指导今后丙肝治疗方案及预后评价提供依据。方法本研究共纳入CHC患者348例，所有患者均接受标准干扰素治疗48周并随访24周。利用Taqman-MGB探针技术，对CCR5基因上rs10800874和rs746492位点进行基因分型，分析其多态性与患者治疗效果的关系。结果经Logistic回归分析结果显示，与rs10800874 TT基因型的CHC携带者相比，TG（调整OR=1.87，95%CI=1.08~3.25，P=0.026）和GG（调整OR=1.96，95%CI=1.01~3.82，P=0.048）基因型的携带患者更容易获得持续性病毒学应答（sustained virological response，SVR）。分层分析发现，在女性、高葡萄糖水平以及低甲胎蛋白水平亚组中，携带rs10800874-G等位基因与SVR之间的仍然显著相关（所有P<0.05）。结论 CCR5 rs10800874-G等位基因是CHC患者接受标准干扰素治疗获得SVR的保护因素。
- 受体,CCR5 /
- 肝炎,丙型,慢性 /
- 多态性,单核苷酸 /
- 干扰素类
Abstract: Objective To explore the association between C-C chemokine receptor type 5 (CCR5) gene polymorphisms and the effectiveness of interferon (IFN) therapy in chronic hepatitis C (CHC) patients, so as to provide a basis for guiding CHC treatment and prognosis evaluation. Methods A total of 348 CHC were included in this study. All patients received standard 48-week IFN therapy and were followed up for 24 weeks. Two single nucleotide polymorphisms (SNPs) rs10800874 and rs746492 in CCR5 gene were genotyped by Taqman-MGB methods, and the relationship between the SNPs and the treatment effectiveness was analyzed. Results Logistic regression analysis showed that CHC patients carrying the rs10800874 TG (adjusted OR=1.87, 95% CI=1.08-3.25, P=0.026) and GG (adjusted OR=1.96, 95% CI 1.01-3.82, P=0.048) genotypes were more likely to have a sustained virological response (SVR), compared with CHC patients carrying TT genotype. The results of further stratified analysis demonstrated that the association between carrying the rs10800874-G allele and SVR in females, high glucose levels and low alpha-fetoprotein levels remained significant (all P<0.05). Conclusions The CCR5 rs10800874-G allele is a protective factor for SVR among CHC patients receiving standard IFN therapy.
- Receptors, CCR5 /
- Hepatitis C, Chronic /
- Polymorphism, Single Nucleotide /
- Interferons